{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. R. 4187"}, "official-title": {"#tail": "\n\t", "#text": "To amend title XVIII of the Social Security Act to encourage the development and use of new\n\t\t\t antimicrobial drugs, and for other purposes."}, "session": {"#tail": "\n\t\t", "#text": "2d Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20140311", "#text": "March 11, 2014"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": [{"#tail": ", and in addition to the Committee on ", "@committee-id": "HWM00", "#text": "Committee on Ways and Means"}, {"#tail": ", for a period to be subsequently determined by the Speaker, in each case for consideration of such\n\t\t\t provisions as fall within the jurisdiction of the committee concerned", "@committee-id": "HIF00", "#text": "Energy and Commerce"}], "sponsor": {"#tail": " (for himself and ", "#text": "Mr. Roskam", "@name-id": "R000580"}, "cosponsor": {"#tail": ") introduced the following bill; which was referred to the ", "#text": "Mr. Danny K. Davis of Illinois", "@name-id": "D000096"}}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "H075BD7DBBAAB47F9AE15EB6FDB2E9636", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": [{"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014", "@value": "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014", "@proposed": "true"}, "#text": "\n            "}, "#tail": " and as the ", "#text": "\n          "}, {"short-title": {"#tail": "\n        ", "#text": "DISARM Act of 2014"}, "#tail": ".", "#text": "\n          "}], "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "H54F6C21DF19144DBB8F3F700EE2DF507"}, {"#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n\t\t\t", "#text": "Encouraging the development and use of new antimicrobial drugs"}, "subsection": [{"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Additional payment for new antimicrobial drugs under Medicare"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the\n\t\t\t end the following new subparagraph:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 1886(d)(5) of the Social Security Act", "@value": "Social Security Act/s:1886/ss:d/p:5"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "42 U.S.C. 1395ww(d)(5)", "@value": "usc/42/1395ww/d/5"}, "@parsable-cite": "usc/42/1395ww", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "In general"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n\t\t\t\t", "@id": "HD361DBA67E864287ACF99D5DF2A2B7A3", "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t\t", "subparagraph": {"@indent": "up2", "#tail": "\n            ", "clause": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall, after notice\n\t\t\t and opportunity for public comment (in the publications required by\n\t\t\t ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " for a fiscal year or otherwise), recognize the costs of\n\t\t\t new antimicrobial drugs under the payment system established under this\n\t\t\t subsection.", "@entity-type": "act", "#text": "subsection (e)(5)", "@value": "Social Security Act/s:1886/ss:e/p:5"}], "#text": "Effective for discharges beginning on or after October 1, 2014, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "@display-inline": "yes-display-inline", "#text": "\n                ", "@id": "H1F92A984F6174CA68AA1639B36CCA4B3", "@commented": "no"}, {"@indent": "up1", "#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-type": "act", "#text": "clause (i)", "@value": "Social Security Act/s:1886/ss:d/p:5/sp:M/cl:i", "@proposed": "true"}, {"#tail": " shall provide for additional payment to be made under this\n\t\t\t subsection with respect to discharges involving new antimicrobial drugs in\n\t\t\t the amount provided for under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " for drugs and biologicals that\n\t\t\t are described in ", "@entity-type": "act", "#text": "section 1847A", "@value": "Social Security Act/s:1847A"}, {"#tail": ".", "@entity-type": "act", "#text": "section 1842(o)(1)(C)", "@value": "Social Security Act/s:1842/ss:o/p:1/sp:C"}], "#text": "Pursuant to ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "#text": "\n                ", "@id": "HE21AC7A55FA9427DA6ED746D310044F0"}, {"@indent": "up1", "#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " on or after January\n\t\t\t 1, 2014, and that\u2014", "@entity-type": "federal-body", "#text": "Federal Food and Drug Administration", "@entity-id": "7524"}, "term": {"#tail": " means a product that is approved for use, or a product for which an indication is first approved\n\t\t\t for use, by the ", "#text": "new antimicrobial drug"}, "#text": "For purposes of this subparagraph, the term ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(iii)"}, "subclause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", in consultation with the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " and the infectious disease\n\t\t\t professional community); and", "@entity-type": "federal-body", "#text": "Director of the\n\t\t\t Centers for Disease Control and Prevention", "@entity-id": "7523"}], "#text": "is indicated to treat an infection caused by, or likely to be caused by, a qualifying pathogen (as\n\t\t\t defined under ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ") for which there is an unmet medical need and which is\n\t\t\t associated with high rates of mortality or significant patient morbidity\n\t\t\t (as determined by the ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t (", "@entity-type": "act", "#text": "section 505E(f) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505E/ss:f"}, "@entity-type": "law-citation", "#text": "\n                      ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "uscode", "#text": "21 U.S.C. 355f(f)", "@value": "usc/21/355f/f"}, "@parsable-cite": "usc/21/355f", "#text": "\n                      ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(I)"}, "@id": "H266F13C2AE5B41CD838945136293E296", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall specify to\n\t\t\t the extent available to such facilities, as determined by the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ").", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "is used in facilities that participate in the Antimicrobial Use and Resistance Module of the\n\t\t\t National Healthcare Safety Network of the Centers for Disease Control and\n\t\t\t Prevention (or, in the case that such Module is not available, is used in\n\t\t\t facilities that participate in such successor or similar reporting module\n\t\t\t or program relating to antimicrobials as the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(II)"}, "@id": "H30891E5F0C5C43D7B1E4880A84968A5F", "#text": "\n                  "}], "#text": "\n                ", "@id": "H9EAA684BFA5E4F25ABDB2FD0A4E1D6C0"}, {"@indent": "up1", "#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall first publish in the Federal Register a list of\n\t\t\t the new antimicrobial drugs.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "Not later than July 1, 2014, the "}, "enum": {"#tail": "\n                ", "#text": "(iv)"}, "#text": "\n                ", "@id": "H613FFE2CD4E34A47B76D88417D7267BE"}], "enum": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "(M)"}, "#text": "\n              ", "@id": "HF0DCBA92B3574338A640B3E2309EF3EC"}}, "#text": "\n          ", "@id": "H1D0D6F61787046159CFBBA17A38EF3A8"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding\n\t\t\t at the end the following new clause:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 1886(d)(3)(C) of the Social Security Act", "@value": "Social Security Act/s:1886/ss:d/p:3/sp:C"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "42 U.S.C. 1395ww(d)(3)(C)", "@value": "usc/42/1395ww/d/3/C"}, "@parsable-cite": "usc/42/1395ww", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Budget neutrality"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n\t\t\t\t", "clause": {"@indent": "up2", "#tail": "\n            ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall\n\t\t\t further reduce each of the average standardized amounts in an amount equal\n\t\t\t to the amount of the net additional expenditures, if any, in such fiscal\n\t\t\t year resulting from the application of ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (5)(M)", "@value": "Social Security Act/s:1886/ss:d/p:5/sp:M", "@proposed": "true"}], "#text": "For discharges occurring in a fiscal year beginning with fiscal year 2015, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(iii)"}, "header": {"#tail": "\n              ", "#text": "Maintaining budget neutrality for certain antimicrobial drugs"}, "#text": "\n              ", "@id": "HC010F57066ED4273BBEDEB69C8518FC2"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t\t", "@id": "H965CC15A30084A269C34445237FB9D82"}, "#text": "\n          ", "@id": "HCE19341245B945BA89EEAC1170A1BC67"}], "#text": "\n        ", "@id": "H510E3E491D3840B4908C11E65475358D"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Study and report on removing barriers to development of new antimicrobial drugs"}, "paragraph": [{"#tail": "\n        ", "@id": "H1B62E06749244BECAD72A59379593461", "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "Study"}, "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall, in consultation with the ", "@entity-type": "federal-body", "#text": "Comptroller General of the United States", "@entity-id": "0500"}, {"#tail": ", the ", "@entity-type": "federal-body", "#text": "Director of the United\n\t\t\t States Patent and Trademark Office", "@entity-id": "1344"}, {"#tail": ", the ", "@entity-type": "federal-body", "#text": "Director of the National\n\t\t\t Institutes of Health", "@entity-id": "7529"}, {"#tail": ", and the ", "@entity-type": "federal-body", "#text": "Commissioner of Food and Drugs", "@entity-id": "7524"}, {"#tail": ", conduct a study to\u2014", "@entity-type": "federal-body", "#text": "Director\n\t\t\t of the Centers for Disease Control and Prevention", "@entity-id": "7523"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "#text": "\n          ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "identify and examine the barriers that prevent the development of new antimicrobial drugs, as\n\t\t\t defined in ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "; and", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "section 1886(d)(5)(M)(iii) of the Social Security Act", "@value": "Social Security Act/s:1886/ss:d/p:5/sp:M/cl:iii", "@proposed": "true"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42\n\t\t\t U.S.C. 1395ww(d)(5)(M)(iii)", "@value": "usc/42/1395ww/d/5/M/iii", "@proposed": "true"}], "@entity-type": "law-citation", "#text": "\n                "}}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "H0C56C30654E44642A8787649B97B3099", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014/s:2/ss:b/p:1/sp:A", "@proposed": "true"}, "#text": "develop recommendations for actions to be taken in order to overcome any barriers identified under\n\t\t\t "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "HB255A8ED70774A3383D841E365BBE1CA", "#text": "\n            "}]}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall\n\t\t\t submit to ", "@entity-type": "federal-body", "#text": "Comptroller General", "@entity-id": "0500"}, {"#tail": " a report on the study conducted under ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014/s:2/ss:b/p:1", "@proposed": "true"}], "#text": "Not later than one year after the date of the enactment of this Act, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Report"}, "#text": "\n          ", "@id": "H92583E8C619647FDB3D3F5399DFEC4AC"}], "#text": "\n        ", "@id": "H68D80C9BA79247788488F86F0782FA05"}], "#text": "\n      ", "@id": "HF052E85DC75C469BA9F66B65B1A1FEB8"}], "#text": "\n\t\t", "@id": "H73AE25BCFBCD420FAE6F6E0BA1EC45F9"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-03-11"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 4187 IH: Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}